Biohaven Ltd (BHVN)
$38.54
Market is closed - opens 7 PM, 26 Apr 2024
Insights on Biohaven Ltd
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.5% return, outperforming this stock by 289.1%
Performance
- $36.83$38.86$38.54
4.44%
Downside
Day's Volatility :5.22%
Upside
0.82%
- $12.35$62.21$38.54
67.96%
Downside
52 Weeks Volatility :80.15%
Upside
38.05%
Returns
| Period | Biohaven Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -13.74% | 0.0% |
6 Months | 38.34% | 0.0% |
1 Year | 194.9% | 2.2% |
3 Years | -48.6% | -23.0% |
Highlights
Market Capitalization | 3.5B |
Book Value | $5.28 |
Earnings Per Share (EPS) | -5.73 |
Wall Street Target Price | 59.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -46.39% |
Return On Equity TTM | -84.44% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -429.1M |
Diluted Eps TTM | -5.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.21 |
EPS Estimate Next Year | -5.95 |
EPS Estimate Current Quarter | -1.41 |
EPS Estimate Next Quarter | -1.39 |
Analyst Recommendation
Buy
92%Buy
7%Hold
0
0%Sell
Based on 13 Wall street analysts offering stock ratings for Biohaven Ltd(by analysts ranked 0 to 5 stars)
Based on 13 analyst
- Current
- 1M Ago
- 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 54.39%
Current $38.54
Target $59.50
Technicals Summary
Sell
Neutral
Buy
Biohaven Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Biohaven Ltd | -29.89% | 38.34% | 194.9% | -48.6% | -39.51% |
 Moderna, Inc. | 1.34% | 41.81% | -16.73% | -38.71% | 314.51% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Biohaven Ltd | NA | NA | NA | -6.21 | -0.84 | -0.46 | NA | 5.28 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Biohaven Ltd | Buy | $3.5B | -39.51% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 314.51% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Stifel Financial Corp
7.61%HHG PLC
7.21%BlackRock Inc
7.04%Suvretta Capital Management, LLC
5.59%State Street Corporation
4.73%T. Rowe Price Associates, Inc.
3.83%
Corporate Announcements
Biohaven Ltd Earnings
Biohaven Ltd’s price-to-earnings ratio stands at None
Read More
Company Information
Organization | Biohaven Ltd |
Employees | 239 |
CEO | Dr. Vladimir Coric M.D. |
Industry | Health Technology |
